{"id":"NCT00090519","sponsor":"Chromaderm, Inc.","briefTitle":"Reduction in the Occurrence of Center-Involved Diabetic Macular Edema","officialTitle":"Reduction in the Occurrence of Center-Involved Diabetic Macular Edema","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-02","primaryCompletion":"2010-04","completion":"2010-04","firstPosted":"2004-08-31","resultsPosted":"2016-05-16","lastUpdate":"2016-10-06"},"enrollment":731,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetic Retinopathy"],"interventions":[{"type":"DRUG","name":"ruboxistaurin","otherNames":["LY333531","Arxxant"]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Ruboxistaurin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine if ruboxistaurin can help slow the worsening of an eye disease called macular edema in patients with diabetes.","primaryOutcome":{"measure":"Mean Duration of Definite Center of Macula-involved Diabetic Macular Edema (DME)","timeFrame":"6 Months through 36 Months","effectByArm":[{"arm":"Ruboxistaurin","deltaMin":1.72,"sd":4.95},{"arm":"Placebo","deltaMin":1.69,"sd":4.41}],"pValues":[{"comp":"OG000 vs OG001","p":"0.969"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":84,"countries":["United States","Australia","Brazil","Canada","Denmark","France","Germany","India","Italy","Mexico","Netherlands","Poland","Portugal","Russia","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":["23404115"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":93,"n":371},"commonTop":["Nasopharyngitis","Hypertension","Cough","Influenza","Headache"]}}